argenx announces Annual General Meeting of Shareholders 26 April 2017

Breda, the Netherlands – argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announces that an annual general meeting of shareholders will be held on Wednesday 26 April 2017.

The shareholders and all other persons with meeting rights are invited to attend the annual general meeting of shareholders, to be held at 9:00 AM on Wednesday 26 April 2017 at Sheraton Amsterdam Schiphol Airport, Schiphol Boulevard 701, 1118 BG Schiphol, the Netherlands.

The formal notice of convocation (including information on attending the meeting in person or by proxy, requirements for notification and registration for the meeting and regarding the e-voting system) is available on the Company's website


The full agenda for the meeting as well as all ancillary documents relevant for the meeting are available via the company website, and are also available for inspection at the Company's offices. A free copy thereof may also be obtained by e-mailing

Next to recurrent items on the agenda such as the discussion and adoption of the 2016 Annual Accounts, discharge of the directors for their duties performed in 2016 and the authorisation of the board of directors to issue shares and to limit or exclude pre-emptive rights in relation thereto, the following is, amongst other, proposed:

  • Approval of the proposed amendment of the articles of association of the Company, converting the Company into a European legal entity of the SE type;
  • Granting a specific authorization to issue shares to the board of directors in relation to a possible NASDAQ listing of the company in 2017;
  • Appointment of A.A. Rosenberg as non-executive director to the board of directors of the Company;
  • Appointment of Deloitte Accountants B.V. for the 2017 financial year.

About argenx

argenx a clinical-stage biotechnology company with a deep pipeline of differentiated antibody-based therapies intended for the treatment of severe auto-immune diseases and cancer. We are focused on developing product candidates that are either first-in-class against novel targets or best-in-class against known, but complex, targets to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies enable us to expand the therapeutic index of our product candidates.

For further information, please contact:

Joke Comijn, Corporate Communications Manager

+32 (0)477 77 29 44

+32 (0)9 243 40 70

Forward-looking Statements

The contents of this announcement include statements that are, or may be deemed to be, forward-looking statements. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms believes, estimates, anticipates, expects, intends, may, will, or should, and include statements argenx makes concerning the intended results of its strategy; its financial condition, results of operation and business outlook; the sufficiency of its cash, cash equivalents and current financial assets; and the momentum of its product candidate pipeline as well as the advancement of, and anticipated clinical development and regulatory milestones and plans related to, argenx’s product candidates and clinical trials. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx’s actual results may differ materially from those predicted by the forward-looking statements. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.